Do you want to read an article? Please log in or register.
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes
Ocular Oncology
Related content
Ocular Oncology
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Eur J Cancer.
Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C
doi: 10.1016/j.ejca.2017.05.038.
COMMENTED
Ocular Oncology
Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1001/jamaophthalmol.2019.5132.
RECOMMENDED
LensesCataracts
5-year outcomes after primary intraocular lens implantation in children aged 2 years or younger with congenital or infantile cataract: findings from the IoLunder2 prospective inception cohort study
Lancet Child Adolesc Health.
Solebo AL, Cumberland P, Rahi JS; British Isles Congenital Cataract Interest Group
doi: 10.1016/S2352-4642
Glaucoma and Ocular PressureOcular Oncology
Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects
Graefes Arch Clin Exp Ophthalmol.
Riechardt AI, Klein JP, Cordini D, Heufelder J, Rehak M, Seibel I, Joussen AM
doi: 10.1007/s00417-018-3929-5.
Ocular Oncology
Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy
JAMA Ophthalmol.
Shields CL, Sioufi K, Srinivasan A, DiNicola M, Masoomian B, Barna LE, Bekerman VP, Say EAT, Mashayekhi A, Emrich J, Komarnicky L, Shields JA
doi: 10.1001/jamaophthalmol.
RECOMMENDED
Further Publications
Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
JAMA Ophthalmol
Heier JS, Brown DM, Shah SP, Saroj N, Dang S, Waheed NK, Wykoff CC, Prenner JL, Boyer DS
doi: 10.1001/jamaophthalmol.2021.0221
RECOMMENDED
Glaucoma and Ocular Pressure
Baseline Central Visual Field Defect as a Risk Factor For NTG Progression: A 5-Year Prospective Study
★ 2
Recommended by
Dr Katarzyna Konieczka, Faculty Member
J Glaucoma.
Raman P, Suliman NB, Zahari M, Mohamad NF, Kook MS, Ramli N
doi: 10.1097/
RECOMMENDED
Ocular Oncology
Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival
★ 2
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
doi: 10.1001/jamaophthalmol.2019.5403.
Uveitis
Incidence and outcome of uveitic glaucoma in eyes with intermediate, posterior or panuveitis followed up to 10 years after randomization to fluocinolone acetonide implant or systemic therapy
Am J Ophthalmol.
Kempen JH, Van Natta ML, Friedman DS, Altaweel MM, Ansari H, Dunn JP, Elner SG, Holbrook JT, Lim LL, Sugar EA, Jabs DA, Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group
doi: 10.1016/j.ajo.2020.06.038.